Key Takeaways After 4 years of soaring sales and profits, analysts are estimating a big flat periodThis could shift on FDA approval for oral Wegovy, the first GLP-1 obesity pill in the USRight now, 8 covering analysts have an average PT of $52, and a high/low of$70/$42Novo Nordisk ((NVO) is a global healthcare company and a prominent player in the diabetes market with a full portfolio of glucagon-like peptide 1 (GLP-1) receptor agonists, modern insulins and human insulins. Based in Bagsværd, Denmark the co ...